Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sinopharm Group Co. Ltd.
  6. News
  7. Summary
    1099   CNE100000FN7

SINOPHARM GROUP CO. LTD.

(1099)
  Report
Delayed Hong Kong Stock Exchange  -  03:08 2022-11-30 am EST
18.44 HKD   +3.25%
04:44aSinopharm to Buy $168 Million Shares in Shyndec Pharma
MT
11/29Sinopharm Unit Wins Nod to Launch Clinical Trial of COVID-19 Nasal Drug
MT
11/18Shanghai Henlius Biotech Renews Existing, Enters New Agreements
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China

09/28/2022 | 04:20pm EST
Government-organised visit to the production line of COVID-19 vaccine by Beijing Institute of Biological Products of Sinopharm's CNBG

NEW YORK (Reuters) - Drugmaker Merck & Co said on Wednesday that it agreed to allow China's Sinopharm to distribute and import its COVID-19 antiviral molnupiravir in China if the drug is approved for use there.

The drugmaker said in a statement that it reached a cooperation framework agreement with Sinopharm that grants the Chinese company distribution and exclusive import rights of the medicine in the China mainland market.

Merck also said it will allow China National Biotec Group, an affiliate of Sinopharm, to make the drug in China and has agreed to transfer technology to help with that production.

Molnupiravir is sold under the brand name Lagevrio in the U.S. Merck developed the pill - and shares the profits equally - with partner Ridgeback Biotherapeutics.

The antiviral pill was once touted as a potential game changer for treating COVID-19, but Paxlovid, a rival drug made by Pfizer Inc, had significantly better results in its clinical trial and has been much more widely used in the United States.

(Reporting by Michael Erman; editing by Jonathan Oatis)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
PFIZER, INC. 1.29% 50.13 Delayed Quote.-16.19%
SAB BIOTHERAPEUTICS, INC. 0.93% 1.08 Delayed Quote.-86.30%
SINOPHARM GROUP CO. LTD. 3.25% 18.44 Delayed Quote.5.31%
All news about SINOPHARM GROUP CO. LTD.
04:44aSinopharm to Buy $168 Million Shares in Shyndec Pharma
MT
11/29Sinopharm Unit Wins Nod to Launch Clinical Trial of COVID-19 Nasal Drug
MT
11/18Shanghai Henlius Biotech Renews Existing, Enters New Agreements
MT
11/04Shanghai Shyndec Pharmaceutical Unit Gets Approval for Injection
MT
10/26Sinopharm Group Co. Ltd. Reports Earnings Results for the Nine Months Ended September 3..
CI
10/26Sinopharm Group Co. Ltd. Reports Earnings Results for the Nine Months Ended September 3..
CI
10/24Sinopharm Q3 Profit Increases 12% to $51.4 Million
MT
10/23China National Medicines' Q3 Profit Rises 6%
MT
10/03ChromaDex Forms Joint Venture to Commercialize Tru Niagen in China; Announces Private P..
MT
09/29Merck & Co. Awards Sinopharm Chinese Distribution Rights For COVID-19 Drug
MT
More news
Analyst Recommendations on SINOPHARM GROUP CO. LTD.
More recommendations
Financials
Sales 2022 571 B 80 673 M 80 673 M
Net income 2022 8 368 M 1 181 M 1 181 M
Net Debt 2022 26 654 M 3 763 M 3 763 M
P/E ratio 2022 6,26x
Yield 2022 4,80%
Capitalization 52 234 M 7 374 M 7 374 M
EV / Sales 2022 0,14x
EV / Sales 2023 0,12x
Nbr of Employees 113 234
Free-Float 43,0%
Chart SINOPHARM GROUP CO. LTD.
Duration : Period :
Sinopharm Group Co. Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINOPHARM GROUP CO. LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 16,74 CNY
Average target price 21,20 CNY
Spread / Average Target 26,7%
EPS Revisions
Managers and Directors
Yong Liu President & Executive Director
Xiao Juan Li Chief Financial Officer
Qing Ming Yu Chairman
Zheng Dong Liu Independent Supervisor
Fu Min Zhuo Independent Non-Executive Director
Sector and Competitors